Rural Americans suffering from early-onset Alzheimer’s are less likely than city dwellers to be seen by specialists and receive tests that can benefit both them and their families, new research has found.
Preeclampsia is a serious complication of pregnancy characterized by high blood pressure and kidney damage. Mayo Clinic researchers found that women with a history of severe preeclampsia have more markers linked to brain cell damage and inflammation, compared to women who had uncomplicated pregnancies.
Timothy Huang, Ph.D., has been awarded $2.8 million by the National Institute on Aging (NIA) to continue his work on Alzheimer’s disease. The four-year project will use human stem cells transplanted into mice to determine the role of specific Alzheimer’s-related gene mutations in the brain.
Researchers found significant differences in movement patterns between participants with normal cognition and those with mild cognitive impairment or Alzheimer’s disease.
Researchers conducted a systematic assessment of more than 200,000 scientific publications to understand the breadth and diversity of biological pathways that contribute to Alzheimer’s disease by research over the last 30 years.
Two new studies offer insights into the factors that may contribute to the disproportionate burden of dementia in non-White and low-income U.S. populations.
The knowledge a medical physicist brings to treatment plans for patients usually focuses on science and technology. But more and more, these scientists are taking the lead on a people-first approach to better health care for those who need it. During the President’s Symposium at the annual AAPM meeting, three keynote speakers will discuss treatment of the Alzheimer’s epidemic, the dynamics of patient engagement, and two research initiatives prioritized by the Biden administration.
Harrington Discovery Institute at University Hospitals and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2022 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer’s disease or related dementias.
The Request for Proposal (RFP) is open to academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada, and the United Kingdom. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer’s field are also encouraged to apply. This award provides a combination of financial support and expert drug development guidance to provide the best chance to move research beyond the bench to the bedside.
Elevated levels of an enzyme called PHGDH in the blood of older adults could be an early warning sign of Alzheimer’s disease. Research led by UC San Diego has consistently found high levels of PHGDH expression in brain tissue and blood samples of older adults with different stages of the disease.
UC San Diego researchers developed a smartphone app that could allow people to screen for Alzheimer’s disease, ADHD and other neurological diseases and disorders—by recording closeups of their eye. The app uses a smartphone’s built-in near-infrared camera and selfie camera to track how a person’s pupil changes in size. These pupil measurements could be used to assess a person’s cognitive condition.
Despite the belief that early diagnosis of Alzheimer’s disease and other dementias is crucial, a new Rutgers study found that the diagnosis may unintentionally impact social relationships and activity.
In a study published in the September issue of the journal Communications Biology, UNLV neuroscientists show that chronic hyperglycemia impairs working memory performance and alters fundamental aspects of working memory networks.
“Alzheimer’s disease is the only top 10 leading causes of death in the US without an effective treatment,” says William Hu, MD, PhD, FAAN. Dr. Hu is Associate Professor and Chief of Cognitive Neurology at Rutgers-RWJ Medical School and Rutgers Institute for Health, Health Care…
In a research letter in JAMA, physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) found that the vast majority of patients who had a diagnosis of either cognitive impairment, Alzheimer’s disease, or Alzheimer’s disease related disorders, including cardiovascular disease, prior stroke, use of blood thinners, and age over 85 years, would have been excluded them from the aducanumab clinical trials.
NeuroVision Imaging Inc. has received an additional investment from the Alzheimer’s Drug Discovery Foundation to hasten development of a novel blood-based lab test to provide detection and measurement of biomarkers for Alzheimer’s disease and other dementias before clinical onset.
NIH Awards $15 million to Wake Forest School of Medicine for Alzheimer’s Research
MINNEAPOLIS – People taking certain drugs to lower blood sugar for type 2 diabetes had less amyloid in the brain, a biomarker of Alzheimer’s disease, when compared to both people with type 2 diabetes not taking the drugs and people without diabetes. The new study, published in the August 11, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology, also found people taking these drugs, called dipeptidyl peptidase-4 inhibitors, showed slower cognitive decline than people in the other two groups.
Research suggests that changes in lifestyle may affect the risk for dementia. Dr. Chen Zhao discusses how changes such as increased physical activity could reduce the risk for dementia.
Only 1 in 10 older adults in a large national survey who were found to have cognitive impairment consistent with dementia reported a formal medical diagnosis of the condition.
A team from Wayne State University recently published the results of a three-year study of cognitive changes in older adults who complained that their cognitive ability was worsening though clinical assessments showed no impairments. MRIs at 18-month intervals showed significant changes in functional connectivity in two areas of the brain.
A new therapy prompts immune defense cells to swallow misshapen proteins, amyloid beta plaques and tau tangles, whose buildup is known to kill nearby brain cells as part of Alzheimer’s disease, a new study shows.
A Rutgers neurologist William T. Hu is available to discuss the new drug, Aduhelm, approved by the Food and Drugs Administration to treat Alzheimer’s. “While there is still a lot of work to be done in understanding this drug, we…
WHAT: Zaldy Tan, MD, a highly respected memory and geriatric medicine specialist at Cedars-Sinai, is available to comment on both sides of the controversy surrounding the Food and Drug Administration’s (FDA) approval of aducanumab for Alzheimer’s. Aducanumab, the scientific name…
The Food and Drug Administration on June 7 approved Aducanumab, which will carry the brand name Aduhelm, as the first new treatment for Alzheimer’s disease in nearly 20 years. Dr. Jeffrey L. Cummings, UNLV research professor and leading expert on Alzheimer’s clinical trials, calls…
The development of dementia, often from Alzheimer’s disease, late in life is associated with abnormal blood levels of dozens of proteins up to five years earlier.
The Health Sciences Division of the Council on Undergraduate Research announces the 2021 recipients of its Mentor Awards, which honor exceptional mentoring and advising by higher education faculty across all subdivisions of health sciences.
ROCKVILLE, MD – Scientists are still a long way from being able to treat Alzheimer’s Disease, in part because the protein aggregates that can become brain plaques, a hallmark of the disease, are hard to study.
The finding could lead to new ways to prevent cold sores and herpes-related eye disease from reoccurring, the researchers report.
NeuroVision Imaging Inc., announced today it has received an investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to support developing reliable, affordable biomarker tests for Alzheimer’s disease and other forms of dementia and neurodegenerative disorders.
A lack of a protein in the brain that keeps our tissues healthy as we age is linked to Alzheimer’s disease, according to recent research from The University of Texas Health Science Center at Houston (UTHealth).
Although cardiologists often decry coconut oil because of certain fats it contains, they overlook the growing evidence that other fatty constituents, especially medium-chain triglycerides, may alleviate some cases of mild cognitive impairment and Alzheimer’s disease
Researchers have identified a family of enzymes whose inhibition both protects neurons and encourages their growth, a pathway to potential new treatments for neurodegenerative diseases from Alzheimer’s to glaucoma.
Researchers at Washington University School of Medicine in St. Louis have found a novel form of the Alzheimer’s protein tau in the fluid surrounding the brain and spinal cord. This form of tau — known as MTBR tau — indicates what stage of Alzheimer’s a person is in and tracks with tangles of tau protein in the brain.
A novel Alzheimer’s disease marker—coming early in progression of the condition—could open significant new fronts of research into possible therapies
As COVID-19 cases increase across the nation, many caregivers are trying to navigate the holidays for relatives with dementia or Alzheimer’s disease. The Centers for Disease Control and Prevention suggests that people not travel to limit the potential spread of the coronavirus.
Mary Catherine Lundquist, program director of Care2Caregivers, a peer counseling helpline (800-424-2494) for caregivers of people with dementia and Alzheimer’s disease operated by Rutgers Behavioral Health Care, discusses how families can stay connected with their loved ones.
Traumatic brain injury (TBI) is a leading cause of cognitive impairment that affects millions of people worldwide. Despite growing awareness about the debilitating and lifelong progressive consequences of TBI, there are currently no treatments that slow the deteriorative process. TBI survivors are currently treated with extensive physical and cognitive rehabilitation, accompanied by medications that may mitigate symptoms yet do not halt or slow neurodegeneration. Now, researchers have found for the first time that this process can be pharmacologically reversed in an animal model of this chronic health condition, offering an important proof of principle in the field and a potential path to new therapy.
in a study with potential impacts on a variety of neurological diseases, Virginia Tech researchers have provided the first experimental evidence from a living organism to show that an abundant, star-shaped brain cell known as an astrocyte is essential for blood-brain barrier health.
Dozens of molecules may tangle up with rogue bundles of tau, a protein that normally gives nerve fibers structure, to cause brain cell damage that contributes to neurodegenerative diseases, a new study shows.
Why do some people stay sharp into their 90s, even if they have the amyloid plaques in the brain that are associated with Alzheimer’s disease? And why do others reach their 90s without ever developing any plaques? These questions are explored in a new study published in the July 22, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Mariana Figueiro, director of the Lighting Research Center, joins the Rutgers University community on Sept. 1 to lead two new programs focused on aging and on sleep and circadian research.
Alzheimer’s disease in its early stages affects the integrity of small blood vessels in the retinas of patients, according to a recent study led by Cedars-Sinai. This discovery holds promise for early diagnosis of Alzheimer’s through the retina, a back-of-the-eye organ that is an extension of the brain and easily accessible for live, noninvasive imaging.
Florida State researchers looked at memory replay in mouse models and found there was impaired functional interactions between the hippocampus and the parietal cortex.
The COVID-19 pandemic and resulting social isolation present unique challenges for more than five million Americans living with Alzheimer’s disease and their caregivers. Monica Townsend, training and consultation specialist at the Comprehensive Services on Aging at Rutgers University Behavioral Health Care, shares how caregivers can cope through the health crisis:
The COVID-19 pandemic is presenting unique challenges for 5M+ Americans living with Alzheimer’s and their caregivers. The recent upending of traditional caregiving resources and structures, across home, adult day services, residential and assisted living facilities and nursing homes, has created new challenges for caregivers. Data from the Alzheimer’s Association indicates 48% of nursing home residents are living with Alzheimer’s or other dementias and among older adults in residential care settings, including assisted living, 42% or more have some form of dementia. Still others receive community-based services, including 32% of individuals using home health services and 31% using adult day services.
The Alzheimer’s Association continues to offer free care and support for families through 24/7 Helpline (800.272.3900) staffed by clinical experts, while local support groups are now being offered via virtual channels for the foreseeable future. Experts including Harry Johns, president
– Report provides latest Alzheimer’s prevalence, incidence, mortality and costs of care data –
– Barring medical breakthroughs, the number of people age 65+ with Alzheimer’s dementia may nearly triple by 2050 –
In the study, a group of lab mice that had consumed a diet that included the HM-10/10 peptide was found to have a significantly lower tumor load than mice that had not eaten the peptide.
Harvard researchers have discovered a new mechanism for how the brain and its arteries communicate to supply blood to areas of heightened neural activity. The findings enable new avenues of study into the role of this process in neurological diseases.
Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson’s disease (PD) and multiple system atrophy (MSA), using a technology developed by a researcher at UTHealth. The discovery was published today in Nature.
Evaluating the effectiveness of therapies for neurodegenerative diseases is often difficult because each patient’s progression is different. A new study shows artificial intelligence (AI) analysis of blood samples can predict and explain disease progression, which could one day help doctors choose more appropriate and effective treatments for patients.
If you’re having difficulty identifying the right word to express yourself clearly or remembering a story correctly, you may blame menopause.